RS63740B1 - Farmaceutski sastav koji se sastoji od inhibitora hmg-coa reduktaze i fenofibrata - Google Patents

Farmaceutski sastav koji se sastoji od inhibitora hmg-coa reduktaze i fenofibrata

Info

Publication number
RS63740B1
RS63740B1 RS20221047A RSP20221047A RS63740B1 RS 63740 B1 RS63740 B1 RS 63740B1 RS 20221047 A RS20221047 A RS 20221047A RS P20221047 A RSP20221047 A RS P20221047A RS 63740 B1 RS63740 B1 RS 63740B1
Authority
RS
Serbia
Prior art keywords
fenofibrate
hmg
pharmaceutical composition
coa reductase
reductase inhibitors
Prior art date
Application number
RS20221047A
Other languages
English (en)
Inventor
Hitendra Netlal Rahangdale
Narendra Bhagwatbhai Prajapati
Satyavan Shivajirao Dhavale
Venkataramana Naidu
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72266598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS63740(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of RS63740B1 publication Critical patent/RS63740B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20221047A 2019-07-31 2020-07-30 Farmaceutski sastav koji se sastoji od inhibitora hmg-coa reduktaze i fenofibrata RS63740B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201921030870 2019-07-31
EP19201186 2019-10-02
PCT/IB2020/057208 WO2021019493A1 (en) 2019-07-31 2020-07-30 Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate
EP20764155.6A EP3833335B1 (en) 2019-07-31 2020-07-30 Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate

Publications (1)

Publication Number Publication Date
RS63740B1 true RS63740B1 (sr) 2022-12-30

Family

ID=72266598

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20221047A RS63740B1 (sr) 2019-07-31 2020-07-30 Farmaceutski sastav koji se sastoji od inhibitora hmg-coa reduktaze i fenofibrata

Country Status (14)

Country Link
US (1) US20220273652A1 (sr)
EP (2) EP4115879A1 (sr)
JP (1) JP2022542004A (sr)
CN (1) CN114173786A (sr)
AU (1) AU2020320448A1 (sr)
BR (1) BR112022001514A2 (sr)
CA (1) CA3148035A1 (sr)
CL (1) CL2022000198A1 (sr)
CO (1) CO2022000808A2 (sr)
ES (1) ES2931301T3 (sr)
MX (1) MX2022001178A (sr)
PL (1) PL3833335T3 (sr)
RS (1) RS63740B1 (sr)
WO (1) WO2021019493A1 (sr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114903862B (zh) * 2022-06-15 2023-08-22 湖北中古生物制药有限公司 一种多廿烷醇阿托伐他汀钙复方制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1415295A (en) 1971-10-14 1975-11-26 Orchimed Sa Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
KR20060085686A (ko) 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트를 포함하는 고형 제제
US20050096391A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
MXPA06003813A (es) 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
CN1993111A (zh) * 2004-05-21 2007-07-04 阿库-伯雷克技术公司 含有相对无活性片段的药片
US20080131503A1 (en) 2005-02-10 2008-06-05 Per Holm Stable Pharmaceutical Composition Comprising a Fixed Dose Combination of Fenofibrate and an Hmg-Coa Reductase Inhibitor
WO2008075320A2 (en) * 2006-12-21 2008-06-26 Ranbaxy Laboratories Limited Antilipidemic pharmaceutical compositions and process for preparation thereof
JP2011525901A (ja) 2008-06-27 2011-09-29 アブディ イブラヒム イラク サナイ ベ ティカレット アノニム シルケティ ロスバスタチンカルシウム含有医薬組成物
US20110311625A1 (en) * 2010-06-14 2011-12-22 Amruth Gowda Doddaveerappa Solid dosage forms of fenofibrate
CN103356500A (zh) * 2012-03-30 2013-10-23 肖广常 一种瑞舒伐他汀钙非诺贝特酸胆碱盐择时渗透泵控释片及其制备方法
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형

Also Published As

Publication number Publication date
ES2931301T3 (es) 2022-12-28
WO2021019493A1 (en) 2021-02-04
PL3833335T3 (pl) 2023-01-02
AU2020320448A1 (en) 2022-02-17
BR112022001514A2 (pt) 2022-03-22
CN114173786A (zh) 2022-03-11
CA3148035A1 (en) 2021-02-04
CL2022000198A1 (es) 2022-09-23
EP3833335A1 (en) 2021-06-16
JP2022542004A (ja) 2022-09-29
EP4115879A1 (en) 2023-01-11
CO2022000808A2 (es) 2022-02-07
EP3833335B1 (en) 2022-08-31
US20220273652A1 (en) 2022-09-01
MX2022001178A (es) 2022-02-22

Similar Documents

Publication Publication Date Title
IL287445A (en) A quinazoline compound and its pharmacologic use
EP3938369A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP3914357A4 (en) TYK2 INHIBITORS AND THEIR USES
EP4003319A4 (en) HDAC6 INHIBITORS AND THEIR USES
IL291191A (en) cdk inhibitors and their use as drugs
EP3634460A4 (en) S-NITROSOGLUTATHION (GSNO) AND GSNO-REDUCTASE INHIBITORS FOR USE IN THERAPY
EP4028385A4 (en) USP30 INHIBITORS AND USES THEREOF
EP4023227A4 (en) PHARMACEUTICAL COMPOSITION AND ITS APPLICATION
IL281357B (en) cd73 inhibitors and their pharmaceutical uses
IL285595A (en) Spt5 inhibitors and uses thereof
EP4218765A3 (en) Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors
PH12015502706A1 (en) Oral formulation for the treatment of cardiovascular diseases
PL3833335T3 (pl) Kompozycja farmaceutyczna zawierająca inhibitory reduktazy HMG-CoA i fenofibrat
EP3999056A4 (en) PHARMACEUTICAL COMBINATION AND USE THEREOF
SG11201801382UA (en) PHARMACEUTICAL COMPOSITION COMPRISING AN HMG-CoA REDUCTASE INHIBITOR AND AN ACE INHIBITOR
PT3833335T (pt) Composição farmacêutica compreendendo inibidores de hmg-coa redutase e fenofibrato
IL291895A (en) mcl1 inhibitors and their uses
EP3852750A4 (en) ALDOKETO REDUCTAE INHIBITORS AND THEIR USES
EP4017857A4 (en) METTL 16 INHIBITORS AND THEIR USES
EP3992189A4 (en) QUINAZOLINE AND CINNOLINE DERIVATIVES AS DNA-PK INHIBITORS
EP3995480A4 (en) AKR1C3 INHIBITOR AND MEDICAL USE
EP4069233A4 (en) PHARMACEUTICAL COMBINATION AND USE THEREOF
EP3919474A4 (en) HBV INHIBITOR AND ITS USE
EP3976009A4 (en) BAX INHIBITORS AND THEIR USES
EP3674303A4 (en) NEW TRYPTOPHANE HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION WITH IT